Tiraboschi Pietro, Attems Johannes, Thomas Alan, Brown Andrew, Jaros Evelyn, Lett Debbie J, Ossola Maria, Perry Robert H, Ramsay Lynne, Walker Lauren, McKeith Ian G
From the Division of Neurology V and Neuropathology (P.T.), IRCCS Foundation, Carlo Besta Neurologic Institute, Milan, Italy; Institute for Aging and Health (J.A., A.T., A.B., E.J., D.J.L., R.H.P., L.R., L.W., I.G.M.), Wolfson Research Center, Campus for Aging and Vitality, Newcastle University, Newcastle upon Tyne, UK; and Division of Neurology and Neurophysiology (M.O.), Azienda Ospedaliera di Busto Arsizio, Presidio di Tradate, Italy.
Neurology. 2015 Feb 3;84(5):496-9. doi: 10.1212/WNL.0000000000001204. Epub 2014 Dec 31.
To investigate whether an increasing load of β-amyloid and/or neuritic plaques influences the phenotype, and thus the clinical diagnostic accuracy, of dementia with Lewy bodies (DLB).
A series of 64 subjects with autopsy-proven DLB was studied. Last diagnosis before death was used to determine the clinical diagnostic accuracy of DLB in relation to Lewy body distribution and extent of Alzheimer β-amyloid and/or neuritic pathology. DLB pathologic diagnosis was made according to consensus criteria, using α-synuclein immunostaining for Lewy body identification. β-Amyloid immunostaining was used for quantifying β-amyloid deposits. The Consortium to Establish a Registry for Alzheimer's Disease criteria and Braak stage were applied for semiquantitative grading of neuritic plaque and neurofibrillary tangle pathology.
Overall clinical diagnostic accuracy for the entire DLB cohort was high (80%), reflecting the high prevalence of core clinical features (fluctuations [81%], parkinsonism [77%], visual hallucinations [70%]). Lower frequencies of core clinical features of DLB, resulting in lower accuracy of its clinical diagnosis, were associated with decreasing Lewy body distribution (p < 0.0001) and with increasing neuritic plaque pathology (p = 0.035), but not with the number of β-amyloid plaque deposits.
The likelihood of occurrence of the DLB clinical syndrome is positively related to the extent of Lewy body pathology and negatively related to the severity of Alzheimer neuritic pathology, while β-amyloid load has no effect.
研究β-淀粉样蛋白和/或神经炎性斑块负荷增加是否会影响路易体痴呆(DLB)的表型,进而影响其临床诊断准确性。
对64例经尸检证实为DLB的受试者进行了研究。死亡前的最后诊断用于确定DLB在路易体分布以及阿尔茨海默β-淀粉样蛋白和/或神经炎性病理程度方面的临床诊断准确性。DLB病理诊断根据共识标准进行,使用α-突触核蛋白免疫染色来识别路易体。β-淀粉样蛋白免疫染色用于量化β-淀粉样蛋白沉积。应用阿尔茨海默病注册协会标准和Braak分期对神经炎性斑块和神经原纤维缠结病理进行半定量分级。
整个DLB队列的总体临床诊断准确性较高(80%),这反映了核心临床特征(波动[81%]、帕金森综合征[77%]、视幻觉[70%])的高患病率。DLB核心临床特征的频率较低,导致其临床诊断准确性较低,这与路易体分布减少(p < 0.0001)和神经炎性斑块病理增加(p = 0.035)相关,但与β-淀粉样蛋白斑块沉积数量无关。
DLB临床综合征的发生可能性与路易体病理程度呈正相关,与阿尔茨海默神经炎性病理严重程度呈负相关,而β-淀粉样蛋白负荷无影响。